Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised …

MC Garassino, O Martelli, M Broggini, G Farina… - The lancet …, 2013 - thelancet.com
Background Erlotinib is registered for treatment of all patients with advanced non-small-cell
lung cancer (NSCLC). However, its efficacy for treatment of patients whose tumours are …
被引用次数：588 相关文章

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised …

MC Garassino, O Martelli, M Broggini, G Farina… - 2013 - pubmed.ncbi.nlm.nih.gov
Background Erlotinib is registered for treatment of all patients with advanced non-small-cell
lung cancer (NSCLC). However, its efficacy for treatment of patients whose tumours are …

[引用][C] Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised …

MC Garassino, O Martelli, M Broggini, G Farina… - The Lancet …, 2013 - cir.nii.ac.jp
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell
lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial | CiNii …

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised …

MC Garassino, O Martelli, M Broggini, G Farina… - The Lancet …, 2013 - Elsevier
Background Erlotinib is registered for treatment of all patients with advanced non-small-cell
lung cancer (NSCLC). However, its efficacy for treatment of patients whose tumours are …

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): A randomised …

MC Garassino, O Martelli, M Broggini, G Farina… - THE LANCET …, 2013 - air.unimi.it
Background: Erlotinib is registered for treatment of all patients with advanced non-small-cell
lung cancer (NSCLC). However, its efficacy for treatment of patients whose tumours are …

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised …

MC Garassino, O Martelli, M Broggini, G Farina… - The Lancet …, 2013 - infona.pl
Erlotinib is registered for treatment of all patients with advanced non-small-cell lung cancer
(NSCLC). However, its efficacy for treatment of patients whose tumours are EGFR wild-type …

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised …

MC Garassino, O Martelli, M Broggini, G Farina… - The Lancet …, 2013 - europepmc.org
Background Erlotinib is registered for treatment of all patients with advanced non-small-cell
lung cancer (NSCLC). However, its efficacy for treatment of patients whose tumours are …

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised …

MC Garassino, O Martelli, M Broggini, G Farina… - The Lancet …, 2013 - thelancet.com
Background Erlotinib is registered for treatment of all patients with advanced non-small-cell
lung cancer (NSCLC). However, its efficacy for treatment of patients whose tumours are …

[引用][C] Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised …

MC Garassino, O Martelli, M Broggini, G Farina… - Lancet …, 2013 - Elsevier Limited